The Trump administration has cancelled a $258 million programme that was working to develop vaccines against HIV, dealing a major blow to efforts to find a cure for the disease that causes AIDS.
The decision affects research teams at two leading American universities who were making important pro
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
Oluwatosin Ogunjuyigbe
Oluwatosin Ogunjuyigbe is a writer and journalist who covers business, finance, technology, and the changing forces shaping Nigeria’s economy. He focuses on turning complex ideas into clear, compelling stories.
